Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Real world evidence

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Real world evidence. Displaying page 1 of 1.
    EudraCT Number: 2017-001054-34 Sponsor Protocol Number: D0816C00018 Start Date*: 2018-01-11
    Sponsor Name:AstraZeneca AB
    Full Title: LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) FR (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000573-80 Sponsor Protocol Number: APHP201075 Start Date*: 2021-05-10
    Sponsor Name:APHP DRCI
    Full Title: Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI), and randomized to Subcutaneous Evolocumab or Normal strategies to ...
    Medical condition:
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005094-28 Sponsor Protocol Number: VAC3_COVID-19_antibody_study_V1 Start Date*: 2021-10-21
    Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology
    Full Title: Population-based prospective, clinical study on efficacy and safety of a booster COVID-19 vaccination
    Medical condition: SARS-CoV-2 infection prevention
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000265-33 Sponsor Protocol Number: 3000LM Start Date*: 2021-02-25
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations
    Medical condition: RPE65-associated inherited retinal degeneration
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001407-31 Sponsor Protocol Number: D5160C00022 Start Date*: 2015-10-28
    Sponsor Name:AstraZeneca AB
    Full Title: Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-...
    Medical condition: Stage IIIB or IV EGFRm NSCLC with T790M positive mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) IT (Completed) AT (Completed) DK (Completed) ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000734-30 Sponsor Protocol Number: D0816C00012 Start Date*: 2015-07-10
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed somatic or germli...
    Medical condition: BRCA or HRR+ Mutated Ovarian Cancer Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-005151-83 Sponsor Protocol Number: MUCUS Start Date*: 2018-10-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003065-15 Sponsor Protocol Number: VEG115232 Start Date*: 2013-04-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib
    Medical condition: advanced or metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-003780-21 Sponsor Protocol Number: RP1907 Start Date*: 2020-03-31
    Sponsor Name:Alimentiv Inc.
    Full Title: Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC Study)
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003135-35 Sponsor Protocol Number: ECU-aHUS-403 Start Date*: 2016-06-20
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, BIOMARKERS, AND TREATMENT
    Medical condition: atypical Hemolytic-Uremic Syndrome (aHUS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004851 10019515 Hemolytic uremic syndrome LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004482-89 Sponsor Protocol Number: GBG93 Start Date*: 2018-01-08
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE IV STUDY EVALUATING PALBOCICLIB PLUS ENDOCRINE TREATMENT VERSUS A CHEMOTHERAPY-BASED TREATMENT STRATEGY IN PATIENTS WITH HORMONE RECEPTOR POSITIVE / HER...
    Medical condition: Metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001279-18 Sponsor Protocol Number: NHSCHECK Start Date*: 2021-03-09
    Sponsor Name:King’s College London
    Full Title: Overall Study Name: NHS CHECK - Health & Experiences of staff working at NHS Trusts and Nightingale Hospitals. Embedded RCT Full Title: Effectiveness of a smartphone app-based intervention in impr...
    Medical condition: Mental Health and Wellbeing of Healthcare Staff
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-001727-11 Sponsor Protocol Number: 307940 / 106-20 Start Date*: 2006-03-17
    Sponsor Name:Schering AG, Global Medical Development
    Full Title: A phase III, open-label, prospective, two-armed, multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) ...
    Medical condition: Diffuse large B-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) IE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) HU (Prematurely Ended) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002328-35 Sponsor Protocol Number: CANTABRICO Start Date*: 2020-11-11
    Sponsor Name:AstraZeneca Farmacéutica Spain, S.A
    Full Title: A Phase IIIB, Single Arm Study, of Durvalumab in Combination with Platinum-Etoposide for Untreated Patients with Extensive-Stage Small Cell Lung Cancer reflecting Real World Clinical Practice in Sp...
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-004688-19 Sponsor Protocol Number: MOR208C203 Start Date*: 2015-10-02
    Sponsor Name:MorphoSys AG
    Full Title: A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphom...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) HU (Completed) DE (Completed) ES (Ongoing) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002896-17 Sponsor Protocol Number: ME-401-003 Start Date*: 2019-04-08
    Sponsor Name:MEI Pharma, Inc.
    Full Title: Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib (ME 401) in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies – The ...
    Medical condition: Follicular lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) BE (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004689-11 Sponsor Protocol Number: MOR208C204 Start Date*: 2016-05-24
    Sponsor Name:MorphoSys AG
    Full Title: A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who ...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) FI (Completed) PT (Completed) FR (Completed) AT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) GB (GB - no longer in EU/EEA) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003855-40 Sponsor Protocol Number: MOR208C115 Start Date*: 2022-03-09
    Sponsor Name:MorphoSys AG
    Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref...
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000430-11 Sponsor Protocol Number: RFBU11-I Start Date*: 2011-10-06
    Sponsor Name:G.I.S.E. - SOCIETA'' ITALIANA CARDIOLOGIA INVASIVA
    Full Title: Minimizing Adverse haemmhorragic events by TRansradial access site and systemic Implementation of angioX (MATRIX)
    Medical condition: Real world ACS both Non-ST segment elevation and ST-segment elevation patients undergoing coronary angiography±PCI.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NL (Ongoing) SE (Ongoing) ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 15:42:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA